Nirsevimab Biosimilar – Anti-RSV Monoclonal Antibody for Research from ProteoGenix; catalogue PX-TA1530; research use only.
Know who made it. See the evidence. Buy through one marketplace.
Nirsevimab Biosimilar, also known as Anti-RSV mAb, is a monoclonal antibody (mAb) that is designed to target and neutralize the respiratory syncytial virus (RSV). This biosimilar is a highly specific and potent therapeutic agent that has been developed using advanced biotechnology techniques.
The structure of Nirsevimab Biosimilar is composed of two heavy chains and two light chains, which are joined together by disulfide bonds. The heavy chains consist of a constant region and a variable region, while the light chains only have a variable region. The variable regions of both the heavy and light chains are responsible for the specific binding and neutralization of RSV.
The constant region of Nirsevimab Biosimilar is derived from human immunoglobulin G1 (IgG1), which is the most abundant antibody isotype in the human body. This constant region provides stability and effector functions to the biosimilar, allowing it to effectively target and neutralize RSV.
Nirsevimab Biosimilar is a potent and specific mAb that targets the F protein of RSV. This protein is essential for the virus to enter and infect host cells. By binding to the F protein, Nirsevimab Biosimilar prevents RSV from entering and infecting cells, effectively neutralizing the virus.
In addition to its neutralizing activity, Nirsevimab Biosimilar also has effector functions that help to clear RSV-infected cells. These functions include antibody-dependent cellular cytotoxicity (ADCC) and complement-dependent cytotoxicity (CDC). ADCC involves the recruitment and activation of immune cells, such as natural killer cells, to kill RSV-infected cells. CDC, on the other hand, involves the activation of the complement system to destroy RSV-infected cells.
The combination of neutralizing and effector functions makes Nirsevimab Biosimilar a highly effective therapeutic agent against RSV. It not only prevents the virus from replicating and spreading, but also helps to clear infected cells from the body.
Nirsevimab Biosimilar is a promising therapeutic agent for the prevention and treatment of RSV infections. RSV is a leading cause of respiratory infections, particularly in infants and young children, and can also cause severe illness in older adults and individuals with weakened immune systems.
This biosimilar has shown promising results in preclinical and clinical studies, demonstrating its ability to neutralize RSV and reduce the severity of RSV infections. It has also been shown to have a favorable safety profile, with no serious adverse events reported in clinical trials.
Nirsevimab Biosimilar is currently in the research grade stage, and further studies are being conducted to evaluate its efficacy and safety in different populations. If approved, it has the potential to provide a much-needed treatment option for RSV infections, especially in high-risk individuals.
In addition to its therapeutic applications, Nirsevimab Biosimilar also has potential research applications. Its highly specific and potent activity against RSV makes it a valuable tool for studying the virus and developing new treatments and prevention strategies.
In addition to antibody reagents, Nirsevimab is also frequently used in assay development workflows. For example, antibodies targeting RSV may serve as controls or reference reagents in immunoassays such as ELISA designed to study antibody binding or viral antigen detection.
Dedicated ELISA tools may be used alongside monoclonal antibodies in studies requiring antibody quantification or assay validation.
In summary, Nirsevimab Biosimilar – Anti-RSV mAb is a highly specific and potent monoclonal antibody that targets and neutralizes RSV. Its unique structure and effector functions make it a promising therapeutic agent for the prevention and treatment of RSV infections. Further research and clinical trials are needed to fully evaluate its potential, but it has the potential to make a significant impact in the fight against RSV.
The price of the Nirsevimab biosimilar depends on the selected size and format. Current pricing is displayed directly on the product page for each available quantity.
ProteoGenix catalogue number PX-TA1530. For research use only.
Target: Nirsevimab Biosimilar – Anti-RSV; Clonality: Monoclonal Antibody; Expression system: Mammalian cells; Purity: >85%; Buffer: PBS buffer PH7.5; Applications: ELISA, WB.
Available configurations: 50ug, 100ug, 1mg, 10mg, 25mg.
Fully tested in-house by ABMIUM, or supported by an advanced validation report from a partner reviewed by ABMIUM. Highest confidence. Non-conformities fully supported under the ABMIUM Product Promise.
Quality verified. Independent collaborator or expected-performance data available. Product meets ABMIUM quality standards.
Expected to work based on structural and biochemical data. Not yet directly tested by ABMIUM or a collaborator. No non-conformity support for this combination.
Not recommended for this application or species/sample combination. This may indicate either evidence of unsuitability or that the combination has not been tested and therefore cannot currently be recommended.
Evidence status by application and model.
| Target | WB | IHC-P | IHC-Fr | IF/ICC | Flow Cyt | IP | ChIP | ELISA |
|---|---|---|---|---|---|---|---|---|
| Nirsevimab Biosimilar – Anti-RSV |
This product is manufactured by ProteoGenix and sold through ABMIUM without relabelling.
ABMIUM supports global orders. Availability, shipping requirements and applicable import arrangements are confirmed before fulfilment where required.
Yes. Send your target, sample, application and experimental conditions through ABMIUM MATCH or technical support.
Unless the listing expressly states otherwise, ABMIUM products are supplied for research use only and are not for diagnostic or therapeutic use.
